Harashima Nanae, Kurihara Kiyoshi, Utsunomiya Atae, Tanosaki Ryuji, Hanabuchi Shino, Masuda Masato, Ohashi Takashi, Fukui Fumiyo, Hasegawa Atsuhiko, Masuda Takao, Takaue Yoichi, Okamura Jun, Kannagi Mari
Department of Immunotherapeutics, Tokyo Medical and Dental University, Medical Research Division, Tokyo, Japan.
Cancer Res. 2004 Jan 1;64(1):391-9. doi: 10.1158/0008-5472.can-03-1452.
Adult T-cell leukemia (ATL) caused by human T-cell leukemia virus type I (HTLV-I) is characterized by poor prognosis after chemotherapy. Recent clinical trials have indicated, however, that allogeneic but not autologous hematopoietic stem cell transplantation (HSCT) for ATL can yield better clinical outcomes. In the present study, we investigated cellular immune responses of ATL patients who obtained complete remission after nonmyeloablative allogeneic peripheral blood HSCT from HLA-identical sibling donors. In the culture of peripheral blood mononuclear cells (PBMCs) from a post-HSCT but not pre-HSCT ATL patient, CD8(+) CTLs proliferated vigorously in response to stimulation with autologous HTLV-I-infected T cells that had been established before HSCT in vitro. These CTLs contained a large number of monospecific CTL population directed to a HLA-A2-restricted HTLV-I Tax 11-19 epitope. The frequency of Tax 11-19-specific CD8+ CTLs in this patient markedly increased also in vivo after HSCT, as determined by staining with HLA-A2/Tax 11-19 tetramers. Similar clonal expansion of HTLV-I Tax-specific CTLs exclusively directed to a HLA-A24-restricted Tax 301-309 epitope was observed in the PBMCs from another ATL patient after HSCT from a HTLV-I-negative donor. Among four post-HSCT ATL patients tested, HTLV-I-specific CTLs were induced in the PBMC culture from three patients but not from the remaining one who had later recurrence of ATL. These observations suggested that reconstituted immunity against antigen presentation in ATL patients after HSCT resulted in strong and selective graft-versus-HTLV-I response, which might contribute to graft-versus-leukemia effects.
由I型人类T细胞白血病病毒(HTLV-I)引起的成人T细胞白血病(ATL)的特点是化疗后预后较差。然而,最近的临床试验表明,ATL患者接受异基因而非自体造血干细胞移植(HSCT)可产生更好的临床结果。在本研究中,我们调查了非清髓性异基因外周血HSCT后获得完全缓解的ATL患者的细胞免疫反应,供者为HLA相同的同胞。在一名HSCT后而非HSCT前的ATL患者的外周血单个核细胞(PBMC)培养中,CD8(+)CTL在受到HSCT前体外建立的自体HTLV-I感染T细胞刺激后强烈增殖。这些CTL包含大量针对HLA-A2限制性HTLV-I Tax 11-19表位的单特异性CTL群体。通过HLA-A2/Tax 11-19四聚体染色测定,该患者中Tax 11-19特异性CD8+CTL的频率在HSCT后体内也显著增加。在另一名ATL患者接受来自HTLV-I阴性供者的HSCT后,在其PBMC中观察到类似的仅针对HLA-A24限制性Tax 301-309表位的HTLV-I Tax特异性CTL的克隆性扩增。在检测的4名HSCT后的ATL患者中,3名患者的PBMC培养中诱导出了HTLV-I特异性CTL,而另一名后来复发ATL的患者则未诱导出。这些观察结果表明,HSCT后ATL患者针对抗原呈递的免疫重建导致了强烈且选择性的移植物抗HTLV-I反应,这可能有助于移植物抗白血病效应。